Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of a primary Sjögren´s Syndrome~* ESSDAI score ≥ 6~* Liver values above 1,5 ULN~* Stable low dose systemic use of Glucocorticoids（\<=7.5mg） in the last 4 weeks before begin with Study medication~Exclusion Criteria:~* Secondary Sjögren's Syndrome~* Pre-treatment with Cyclosporine A~* Receiving cyclosphosphamide, corticosteroid bolus with dose over 1 mg/kg, rituximab, belimumab, other immunosuppressives~* Infection~* Neoplasia~* Relevant cardiac, pulmonary, neurologic or psychiatric disease~* Life-Vaccination within 4 weeks before begin with study medication~* Pregnant or breast-feeding~* Weight under 45kg or more than 80kg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Experimental: hrIL-2 active (Type: ACTIVE_COMPARATOR): Intervention：Add hrIL-2 according to the protocol to original treatment. HrIL-2 active: 1 million U doses of human recombinant interleukin-2 s.c. injection
- Placebo Comparator: hrIL-2 placebo (Type: PLACEBO_COMPARATOR): 1 million U doses of placebo s.c. injection

Based on this trial design, predict the completion outcome and termination type (if applicable).